logo

Company’s Banking Stock: Dissecting a -53.52% Quarterly Revenue Decline Amid Growth

ALXO Stock

Moderna Inc’s stock market performance has been somewhat irregular. The 1-year high for the company’s stock was recorded at $170.47 on 05/24/24, with the lowest value being $52.26 on 10/24/24.

52-week price history of MRNA Stock

Analyzing the 52-week price history of a stock, including its high and low prices, can provide valuable insight into its current status and potential future performance. Moderna Inc’s current trading price is -67.49% away from its 52-week high, while its distance from the 52-week low is 6.04%. The stock’s price range for this period has remained between $52.26 and $170.47. The Healthcare sector company’s shares managed to surpass a trading volume of around 2.5 million for the day, which was noticeably lower compared to the shares’ average daily volume of 5.05 million over the last three months.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Financial Performance and Market Capitalization

Moderna Inc (MRNA) has experienced a quarterly decline of -53.52% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 21.30B and boasts a workforce of 5600 employees.

Moving average and trading volume data

Based on Barchart.com data, the company’s moving average over the 100-day period was 91.31, with a change in price of -99.11. Similarly, Moderna Inc recorded 4,419,867 in trading volume during the last 100 days, posting a change of -64.07%.

MRNA Debt-to-equity ratio analysis

The debt-to-equity (D/E) ratio is a valuable metric that offers insight into a company’s financial health and standing in the market. This ratio is calculated by dividing a company’s current total liabilities by its shareholders’ equity. The D/E ratio illustrates the extent of debt a company is utilizing to support its assets in relation to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for MRNA stands at 0.11. Similarly, the long-term debt-to-equity ratio is also 0.11.

MRNA Stock Stochastic Average

As of today, the raw stochastic average of Moderna Inc over the last 50 days is at 8.84%. This shows a declinee from the raw stochastic average of the previous 20 days, which was recorded at 29.05%. Further, the company’s Stochastic %K and %D values for the last 20 days were 16.98% and 9.90%, respectively.

MRNA Stock Price Performance Analysis

The stock price performance this year has been a mixed bag, which means people have different opinions about whether it’s been good or bad. Some may see it as optimistic, while others may view it as pessimistic. Until today this year the stock’s price performance recorded a decrease of -44.28%. However, over the last six months, the performance has been stronger by -49.76%. The price of MRNA decreased -17.08% over the last 30 days. And in the last five days, it has surged by 3.78%.

Most Popular